Determination of MIC breakpoints for second-line drugs associated with clinical outcomes in multidrug-resistant tuberculosis treatment in China

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4786-4792

  Zheng, Xubin ^a   Zheng, Rongrong ^b   Hu, Yi ^a,c   Werngren, Jim ^d   Forsman, Lina Davies ^c,e   Mansjö, Mikael ^d   Xu, Biao ^a   Hoffner, Sven ^c,d  

^a FUDAN UNIVERSITY   (China)

^b Xiamen Center for Disease Prevention and Control   (China)

^c KAROLINSKA INSTITUTE   (Sweden)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; DECISION TREE; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPUTUM CULTURE; ADOLESCENT; AGED; COMBINATION DRUG THERAPY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMIKACIN; ANTITUBERCULAR AGENTS; CHINA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PROSPECTIVE STUDIES; PYRAZINAMIDE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84979544166     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03008-15     Document Type: Article

References (33)

1. Zumla A, George A, Sharma V, Herbert RH, Oxley A, Oliver M. 2015. The WHO 2014 global tuberculosis report-further to go. Lancet Glob Health 3:e10-e12. http://dx.doi.org/10.1016/S2214-109X(14)70361-4.
2. Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Pena JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D, Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. 2014. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 59:1364-1374. http://dx.doi.org/10.1093/cid/ciu619.
3. Hong-Min W, Xiao-Hong Z. 2015. Association of drug susceptibility testing results for first- and second-line drugs with treatment outcomes in patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 60:1285-1286. http://dx.doi.org/10.1093/cid/ciu1169.
4. Gumbo T. 2010. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 54:1484-1491. http://dx.doi.org/10.1128/AAC.01474-09.
5. Gumbo T, Pasipanodya JG, Wash P, Burger A, McIlleron H. 2014. Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob Agents Chemother 58:6111-6115. http://dx.doi.org/10.1128/AAC.03549-14.
6. Werngren J, Sturegard E, Jureen P, Angeby K, Hoffner S, Schon T. 2012. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. Antimicrob Agents Chemother 56:1253-1257. http://dx.doi.org/10.1128/AAC.05894-11.
7. Schon T, Jureen P, Chryssanthou E, Giske CG, Sturegard E, Kahlmeter G, Hoffner S, Angeby KA. 2011. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis 15:502-509. http://dx.doi.org/10.5588/ijtld.10.0238.
8. Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegard E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schon T. 2010. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother 65:946-952. http://dx.doi.org/10.1093/jac/dkq091.
9. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, Meissner G, Mitchison DA, Sula L. 1963. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 29:565-578.
10. Kent PT, Kubica GP. 1985. Public health mycobacteriology: a guide for the level III laboratory. U.S. Department of Health and Human Services/Public Health Service/Centers for Disease Control and Prevention, Atlanta, GA.
11. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. 2008. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 system. Int J Tuberc Lung Dis 12:1449-1455.
12. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcon E, Cegielski JP, Grzemska M, Gupta R, Espinal M. 2005. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9:640-645.
13. Anonymous. 2013. Definitions and reporting framework for tuberculosis. World Health Organization, Geneva, Switzerland.
14. Anonymous. 2010. Treatment of tuberculosis, Guidelines for National Programmes, 4th ed. World Health Organization, Geneva, Switzerland.
15. Grajski KA, Breiman L, Viana Di Prisco G, Freeman WJ. 1986. Classification of EEG spatial patterns with a tree-structured methodology: CART. IEEE Trans Biomed Eng 33:1076-1086.
16. Steinberg D, Colla P. 1995. CART: tree-structured non-parametric data analysis. Salford Systems, San Diego, CA.
17. Breiman L, Friedman JH, Olshen RA, Stone CJ. 1984. Classification and regression trees. Chapman & Hall/CRC, Washington, DC.
18. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-1473. http://dx.doi.org/10.1093/infdis/jit352.
19. Gumbo T, Chigutsa E, Pasipanodya J, Visser M, van Helden PD, Sirgel FA, McIlleron H. 2014. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J Antimicrob Chemother 69:2420-2425. http://dx.doi.org/10.1093/jac/dku136.
20. Pasipanodya JG, Gumbo T. 2011. A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol 11:457-463. http://dx.doi.org/10.1016/j.coph.2011.07.001.
21. Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, Leff R, van Oers NS, Gumbo T. 2012. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 56:4806-4815. http://dx.doi.org/10.1128/AAC.05546-11.
22. Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP. 2015. Association between regimen composition and treatment response in patients with multidrug-resistant tuberculosis: a prospective cohort study. PLoS Med 12:e1001932. http://dx.doi.org/10.1371/journal.pmed.1001932.
23. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. 2012. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56:3114-3120. http://dx.doi.org/10.1128/AAC.00384-12.
24. Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, Ammerman NC, Pym AS, Wallengren K, Hafner R, Lalloo U, Swindells S, Bishai WR. 2012. Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci U S A 109:15001-15005. http://dx.doi.org/10.1073/pnas.1203636109.
25. Jarlier V, Nikaido H. 1994. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 123:11-18. http://dx.doi.org/10.1111/j.1574-6968.1994.tb07194.x.
26. Ho J, Jelfs P, Sintchenko V. 2014. Fluoroquinolone resistance in nonmultidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int J Infect Dis 26:149-153. http://dx.doi.org/10.1016/j.ijid.2014.03.1388.
27. Jain K, Desai M, Solanki R, Dikshit RK. 2014. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J Pharmacol Pharmacother 5:145-149. http://dx.doi.org/10.4103/0976-500X.130062.
28. Marais E, Mlambo CK, Lewis JJ, Rastogi N, Zozio T, Grobusch MP, Duse A, Victor T, Warren RW. 2014. Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa. Infection 42:405-413. http://dx.doi.org/10.1007/s15010-013-0572-2.
29. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. 2011. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 204:1951-1959. http://dx.doi.org/10.1093/infdis/jir658.
30. Unsal E, Guler M, Ofluoglu R, Capan N, Cimen F. 2013. Factors associated with treatment outcome in 64 HIV negative patients with multidrug resistant tuberculosis. J Thorac Dis 5:435-439.
31. Xie B, Yang Y, He W, Xie D, Jiang G. 2013. Pulmonary resection in the treatment of 43 patients with well-localized, cavitary pulmonary multidrug-resistant tuberculosis in Shanghai. Interact Cardiovasc Thorac Surg 17:455-459. http://dx.doi.org/10.1093/icvts/ivt251.
32. Dhingra VK, Rajpal S, Mittal A, Hanif M. 2008. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic. Indian J Tuberc 55:15-21.
33. Choi H, Lee M, Chen RY, Kim Y, Yoon S, Joh JS, Park SK, Dodd LE, Lee J, Song T, Cai Y, Goldfeder LC, Via LE, Carroll MW, Barry CE, III, Cho SN. 2014. Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012. BMC Infect Dis 14:360. http://dx.doi.org/10.1186/1471-2334-14-360.